[
  {
    "ts": null,
    "headline": "$20 Billion Club: For The Largest Corporate DB Plans, Maximizing Returns Is Not The Goal",
    "summary": "Russell Investments expects the trend toward liability-hedging fixed income to persist as funded status inches upward. We also expect ongoing interest in alternative asset classes.",
    "url": "https://finnhub.io/api/news?id=468745bdb483d27c46aee362eedc06edc9b8f3deba0af40c14a83b479e7a1bb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741105440,
      "headline": "$20 Billion Club: For The Largest Corporate DB Plans, Maximizing Returns Is Not The Goal",
      "id": 132980421,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210533728/image_1210533728.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Russell Investments expects the trend toward liability-hedging fixed income to persist as funded status inches upward. We also expect ongoing interest in alternative asset classes.",
      "url": "https://finnhub.io/api/news?id=468745bdb483d27c46aee362eedc06edc9b8f3deba0af40c14a83b479e7a1bb2"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Avoid Tariff Damage. There Are Other Problems.",
    "summary": "Healthcare Stocks Avoid Tariff Damage. There Are Other Problems.",
    "url": "https://finnhub.io/api/news?id=99d76e164ce2594f8a0e2bbca8fa88e0f0369c84626e30bd797565920f964fa2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741098360,
      "headline": "Healthcare Stocks Avoid Tariff Damage. There Are Other Problems.",
      "id": 132983282,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Avoid Tariff Damage. There Are Other Problems.",
      "url": "https://finnhub.io/api/news?id=99d76e164ce2594f8a0e2bbca8fa88e0f0369c84626e30bd797565920f964fa2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Remains A Good Pick For Dividend Investors",
    "summary": "Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=a94b2aa38b170e7ca579e5c5f87455ee114aa19b573729630b0afc143848224d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741073662,
      "headline": "Pfizer Remains A Good Pick For Dividend Investors",
      "id": 132974424,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=a94b2aa38b170e7ca579e5c5f87455ee114aa19b573729630b0afc143848224d"
    }
  }
]